IMRX logo

IMRXImmuneering Corp

$4.39
$0.11
(2.57%)
Today
Updated: 12:46 PM EDT
Reported EarningsMay 15
Mkt Cap$276.9M
Vol1.07M
News
all
press releases
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.
Stocktwits
News Placeholder
More News
News Placeholder
Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday
Immuneering (NASDAQ:IMRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...
MarketBeat
News Placeholder
Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen
Wall Street Zen raised Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com...
MarketBeat
News Placeholder
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as extraordinary early survival results for the company's...
MarketBeat
News Placeholder
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...
MarketBeat
News Placeholder
Immuneering (IMRX) to Release Earnings on Thursday
Immuneering (NASDAQ:IMRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat
News Placeholder
Immuneering's (IMRX) "Buy" Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Immuneering in a research note on Monday...
MarketBeat
News Placeholder
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Immuneering from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat
<
1
2
...
>